To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.
Patients aged 18 years and older, up to 70 years.
Participants must be able to understand and willing to sign the written informed consent form.
Eastern Cooperative Oncology Group performance status 0 to 3.
Life expectancy ≥3 months (as determined by the investigator).
Patients who have previously received systemic anti-tumor therapy.
Patients with central nervous system involvement.
Patients who received systemic adrenal corticosteroids for more than 5 days within 14 days prior to study drug administration, or who require daily doses of >10 mg of dexamethasone or equivalent drugs to control central nervous system disease.
Active concurrent malignancy requiring active treatment.